The DOI matches its Crossref record; 1 of the 2 references it cites were found in a registry or an index.
1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar results were observed in the KRYSTAL-1 study evaluating adagrasib as monotherapy or in combination with cetuximab in the same populaton.21”
In the citing paper
“TRAEs of grade 3-4 occurred in 34.1% (15/44) of patients who received adagrasib monotherapy, whereas they declined to 15.6% (5/32) in patients who received adagrasib plus cetuximab.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnold, D., Goekkurt, E., Stein, A., Martens, U. M., Chater, J., Ungerechts, G., Loghmani, H., Coffey, M. C., Trauger, R. J., & Heineman, T. C. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.2572 · Cited by 6
Flagged first, then by citations
1 of the 2 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Singhal, A., Li, B. T., & O'Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 380
Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02274-z · Cited by 22
Self-citationCaughey, B. A., & Strickler, J. H. (2023) · Drugs · doi:10.1007/s40265-023-01980-8 · Cited by 15
Pant, S., Arnold, D., Tabernero, J. M., Loriot, Y., Folprecht, G., Haag, G. M., Palmer, D. H., Prenen, H., Coward, J. I. G., Lugowska, I. A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.2570 · Cited by 7
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer
Yamamoto, N., Yan, D., Ganju, V., Hou, X., Pan, H., Shan, J., Wang, L., Kim, S.-W., Richardson, G., Sanborn, R. E., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-025-03286-w · Cited by 5
Self-citation
Metadata
- Authors
- Kondo, S., Yan, D., Ganju, V., Richardson, G., Hou, X., Shan, J., Liu, X., Zhang, Y., Xie, X., Xiang, Z., Shi, Z., Wang, Y., Zhang, L., & Yamamoto, N.
- Affiliations
- National Cancer Center Hospital (JP)
- Beijing Luhe Hospital Affiliated to Capital Medical University (CN)
- Peninsula Health (AU)
- Cabrini Hospital (AU)
- Henan Cancer Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- InventisBio Co., Ltd. (China) (CN)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 34
- Pages
- S898-S899
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4387810506
- Cited by
- 6
- References
- 2
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Array BioPharma
- Boston Scientific Corporation
- Merck KGaA
- Taiho Pharmaceutical
- Exelixis
- Incyte
- Ribon Therapeutics
- NuCana
- Natera
- Eisai
- Astellas Pharma
- European Society for Medical Oncology
- Servier
- Ipsen
- INCLIVA Instituto de Investigación Sanitaria
- Sirtex Medical
- Genentech
- Foundation Medicine
- Daiichi Sankyo Europe
- Cilag
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- KRAS G12C, advanced pancreatic cancer, KRAS mutation, non-small cell lung cancer, colorectal cancer, clinical activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
